AOL Money & Finance

ALTH posts

Feed

Analyst upgrades, downgrades and initiations: WDC, NSTX, UBS, TIF, BA ...

Analyst upgrades:
  • Baird upgraded Western Digital (NYSE: WDC) and Seagate (NASDAQ: NSTX) to Outperform from Neutral citing better than expected industry conditions. The firm believes supply has tightened, resulting in price increases in certain market segments.
  • RBC Capital upgraded XTO Energy (NYSE: XTO) to Outperform from Sector Perform citing free cash flow and stable growth.
  • Goldman upgraded Manpower (NYSE: MAN) to Neutral from Sell and raised its target to $29 from $20 based on balanced risk/reward.
  • Energy Conversion (NASDAQ: ENER) was upgraded to Buy from Neutral at Piper Jaffray.
  • Infineon (NYSE: IFX) was raised to Hold from Sell at RBS.
  • NetSuite (NYSE: N) was upgraded to Acummulate from Source of Funds at ThinkEquity.

Continue reading Analyst upgrades, downgrades and initiations: WDC, NSTX, UBS, TIF, BA ...

Analyst initiations: FSC and HD

MOST NOTEWORTHY: Fifth Street Finance and Home Depot were today's noteworthy initiations:
  • Wachovia believes Fifth Street Finance (NYSE: FSC) is better positioned than many of its peers, especially in the areas of capital and growth. The firm, which started shares with an Outperform rating, believes the company's reduced competition and liquidity should allow it to pick the best investment opportunities.
  • Home Depot (NYSE: HD) was initiated with a Buy rating and $30 target at Rochdale, citing Home Depot's valuation and shift towards maximizing ROIC and cash flow from growth.
OTHER INITITATIONS:

Analyst initiations: RIO, ALTH and TMK

MOST NOTEWORTHY: Vale, Allos Therapeutics and Torchmark were today's noteworthy initiations:
  • Lehman believes Vale (NYSE:RIO) is well-positioned to benefit from rising steel demand in emerging economies. The firm started shares with an Overweight rating and $45 target.
  • Citigroup initiated Allos Therapeutics (NASDAQ:ALTH) with a Buy rating and $11 target and believes the company's lead drug PDX is likely to be the first FDA approved agent for peripheral T cell lymphoma.
  • Friedman Billings expects Torchmark's (NYSE:TMK) sales to get back on track given increased recruiting, ongoing management initiatives, and the potential demise of Medicare Advantage. Shares were assumed with an Outperform rating and $72 target.
OTHER INITIATIONS:

10 Stocks Under $10: Allos Therapeutics (ALTH)

It's time to wrap up our list of 10 stocks under $10. The list was culled from a large grouping of momentum names that have outperformed on a relative-strength basis during the short and intermediate term. The selection was filtered to eliminate any stocks trading above the $10 region, naturally, and then adjusted for other fundamental, technical, and sentiment factors. I hope you've had fun learning about some potential bargains for your portfolio and hearing the stories behind some equities that you've likely not come across in your daily investing research.

The last entry (and these have been in no particular order, by the way) is Allos Therapeutics (NASDAQ: ALTH). The pharmaceutical company is hard at work on technology that improves existing cancer medications. According to Hoovers Online, ALTH's current lead drug candidate -- PDX -- is in trials to combat T-cell lymphoma. Some of the firm's other proposed treatments work to fight solid tumors and lymphoma.

Continue reading 10 Stocks Under $10: Allos Therapeutics (ALTH)

Analyst initiations 5-17-07: DAL, NWS, TFSM and VCLK

MOST NOTEWORTHY: The more noteworthy companies initiated today were ValueClick, Inc (VCLK), Delta Air Lines, Inc (DAL), 24/7 Real Media, Inc (TFSM), Knology, Inc (KNOL) and Allos Therapeutics, Inc (ALTH):
  • Banc of America believes ValueClick Inc (NASDAQ: VCLK) is well-positioned for continued strong secular online ad growth and initiated shares with a Buy rating and $35 target.
  • Lehman is positive on Delta Air Lines (NYSE: DAL) valuation and earnings growth, starting shares with an Overweight rating and $26.50 target.
  • Banc of America believes 24/7 Real Media's (NASDAQ: TFSM) valuation is full at current levels and started shares with a Neutral rating and $12 target.
  • RBC believes shares of Knology (NASDAQ: KNOL) are fairly-valued and would wait for a pullback, initiating shares with a Sector Perform rating.
  • ThinkEquity started Allos Therapeutics (NASDAQ: ALTH) with a Buy rating and expects significant news flow data on PDX in 2007-2008. In addition, the firm expects to hear an update on enrollment from the PROPEL study, which could be ahead of expectations, and Phase I data in NSCLC in the fall...
OTHER INITIATIONS:
  • Goldman resumed coverage with Mylan Laboratories (NYSE: MYL) and Exco Resources, Inc (XCO) with Neutral ratings.
  • Merrill Lynch resumed coverage of News Corp (NYSE: NWS) with a Buy rating.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 25, 2009: 08:02 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance